Unveiling the sumatriptan dose-relief relationship

Key Findings

This article aims to correlate the pharmacokinetic parameters of sumatriptan to the percentage of patients experiencing relief after two hours. Using data from the literature, a two-compartment pharmacokinetic model is developed to compute the concentration of sumatriptan in the brain across various routes of administration and doses. This concentration is then correlated to its clinical effect. The maximum concentration of sumatriptan in the brain correlates linearly with the percentage of patients experiencing pain relief after two hours. Based on the evolution over time of the brain concentration, the action time can also be predicted for different route-dose combinations. The present correlation provides a relationship between the dose of sumatriptan and its effect for multiple routes of administration. The approach developed in this work could be adapted to other molecules to explore their dose-response relationships.

Why This Matters for Body-Mind Practice

[Draft — editorial context needed]

Source

• Unveiling the sumatriptan dose-relief relationship. — European journal of clinical pharmacology